PET evaluation of therapeutic limb perfusion in Merkel's cell carcinoma

J Nucl Med. 1998 Dec;39(12):2087-90.

Abstract

An 87-yr-old woman diagnosed with recurrent Merkel's cell carcinoma was treated with therapeutic limb perfusion and underwent PET scanning with 18F-fluorodeoxyglucose (FDG). PET studies were obtained before and after treatment to determine the response to the intervention. A baseline whole-body study was obtained to assess the extent and degree of disease activity. This was followed by a repeat PET scan 2 mo. later after treatment with isolated limb chemotherapy with high-dose melphalan and tumor necrosis factor-alpha. The initial scan demonstrated multiple foci of high FDG uptake in the left calf, a left supraclavicular lesion and also detected concurrent keratinizing squamous cell metastasis in the right axilla. A repeat PET study showed complete metabolic resolution of the lesions in the left calf after treatment. FDG PET may be a useful technique for staging Merkel cell carcinoma and for assessing the tumor response after therapy of this rare tumor.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Aged, 80 and over
  • Antineoplastic Agents, Alkylating / administration & dosage
  • Antineoplastic Agents, Alkylating / therapeutic use*
  • Carcinoma, Merkel Cell / diagnostic imaging*
  • Carcinoma, Merkel Cell / drug therapy*
  • Chemotherapy, Cancer, Regional Perfusion
  • Female
  • Fluorodeoxyglucose F18
  • Humans
  • Leg
  • Melphalan / administration & dosage
  • Melphalan / therapeutic use*
  • Radiopharmaceuticals
  • Recurrence
  • Skin Neoplasms / diagnostic imaging*
  • Skin Neoplasms / drug therapy*
  • Tomography, Emission-Computed
  • Tumor Necrosis Factor-alpha / administration & dosage
  • Tumor Necrosis Factor-alpha / therapeutic use*

Substances

  • Antineoplastic Agents, Alkylating
  • Radiopharmaceuticals
  • Tumor Necrosis Factor-alpha
  • Fluorodeoxyglucose F18
  • Melphalan